Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

Christopher J. Edwards,Joëlle Monnet,Martin Ullmann,Pantelis Vlachos,V. Chyrok,Vishal Ghori

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

2019

Christopher J. Edwards
Joëlle Monnet
Martin Ullmann
Pantelis Vlachos
V. Chyrok
Vishal Ghori

Objectives To compare the safety, efficacy, and immunogenicityof MSB11022 (acetate-buffered formulation), an adalimumab biosimilar, with the reference product.

Keywords:

TNF inhibitor
Medicine
Biosimilar
Diabetes mellitus
Rheumatoid arthritis
Immunogenicity
Physical therapy
Pharmacology
Adalimumab
Rheumatology
Quality of life
Clinical endpoint
Adverse effect
Internal medicine

Correction
Source
Cite
Save

References

Citations